Immatics (IMTX) Cash from Investing Activities (2019 - 2026)
Immatics (IMTX) posted Cash from Investing Activities of -$33.7 million for Q4 2025, down 123.48% sequentially from $143.4 million in Q3 2025, and up 33.55% YoY from -$25.2 million in Q4 2024.
Analysis
Immatics (IMTX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Immatics has reported Cash from Investing Activities for 7 years, with the latest figure at -$33.7 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 33.55% year-over-year to -$33.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $231.7 million (up 240.78% YoY) and the FY2025 annual result came in at $231.4 million, up 240.28% from the prior year.
- Cash from Investing Activities retreated to -$33.7 million in Q4 2025 per IMTX's latest filing, from $143.4 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $143.4 million in Q3 2025 and troughed at -$262.7 million in Q1 2024.
- A 5-year average of -$8.7 million and a median of -$3.0 million in 2023 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 510.15% in 2024, down 6481.11% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$2.1 million in 2021, then plunged by 4300.84% to -$92.0 million in 2022, then jumped by 169.84% to $64.3 million in 2023, then plunged by 178.82% to -$50.7 million in 2024, then jumped by 33.55% to -$33.7 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$33.7 million, $143.4 million, and $72.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -9.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.48 Mn |
| Mar 31, 2026 | -32.88 Mn |
| Dec 31, 2025 | -33.66 Mn |
| Sep 30, 2025 | 143.39 Mn |
| Jun 30, 2025 | 72.73 Mn |
| Mar 31, 2025 | 49.24 Mn |
| Dec 31, 2024 | -50.66 Mn |
| Sep 30, 2024 | 73.59 Mn |
| Jun 30, 2024 | 75.19 Mn |
| Mar 31, 2024 | -262.70 Mn |
| Dec 31, 2023 | 64.27 Mn |
| Sep 30, 2023 | -76.82 Mn |
| Jun 30, 2023 | -18.33 Mn |
| Mar 31, 2023 | -3.99 Mn |
| Dec 31, 2022 | -92.03 Mn |
| Sep 30, 2022 | -71.65 Mn |
| Jun 30, 2022 | -58.01 Mn |
| Mar 31, 2022 | 6.55 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Sep 30, 2021 | 23.15 Mn |